C-peptide in the classification of diabetes in children and adolescents.
(2012) In Pediatric Diabetes 13. p.45-50- Abstract
- C-peptide in the classification of diabetes in children and adolescents. Aim: To report C-peptide results in newly diagnosed patients and the relation to clinical diagnosis of diabetes. Methods: A nation-wide cohort, the Better Diabetes Diagnosis study was used to determine serum C-peptide at diagnosis in 2734 children and adolescents. Clinical data were collected at diagnosis and follow-up. C-peptide was determined in a validated and controlled time-resolved fluoroimmunoassay. Results: The clinical classification of diabetes, before any information on human leukocyte antigen, islet autoantibodies, or C-peptide was received, was type 1 diabetes (T1D) in 93%, type 2 diabetes (T2D) in 1.9%, maturity onset diabetes of the young (MODY) in... (More)
- C-peptide in the classification of diabetes in children and adolescents. Aim: To report C-peptide results in newly diagnosed patients and the relation to clinical diagnosis of diabetes. Methods: A nation-wide cohort, the Better Diabetes Diagnosis study was used to determine serum C-peptide at diagnosis in 2734 children and adolescents. Clinical data were collected at diagnosis and follow-up. C-peptide was determined in a validated and controlled time-resolved fluoroimmunoassay. Results: The clinical classification of diabetes, before any information on human leukocyte antigen, islet autoantibodies, or C-peptide was received, was type 1 diabetes (T1D) in 93%, type 2 diabetes (T2D) in 1.9%, maturity onset diabetes of the young (MODY) in 0.8%, secondary diabetes (0.6%), while 3.3% could not be classified. In a random, non-fasting serum sample at diagnosis, 56% of the patients had a C-peptide value >0.2 nmol/L. Children classified as T2D had the highest mean C-peptide (1.83 + 1.23 nmol/L) followed by MODY (1.04 ± 0.71 nmol/L) and T1D (0.28 ± 0.25 nmol/L). Only 1/1037 children who had C-peptide <0.2 nmol/L at diagnosis was classified with a type of diabetes other than T1D. Predictive value of C-peptide >1.0 nmol/L for the classification of either T2D or MODY was 0.46 [confidence interval 0.37-0.58]. Conclusions: More than half of children with newly diagnosed diabetes have clinically important residual beta-cell function. As the clinical diagnosis is not always straightforward, a random C-peptide taken at diagnosis may help to classify diabetes. There is an obvious use for C-peptide determinations to evaluate beta-cell function in children with diabetes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2168965
- author
- Ludvigsson, Johnny ; Carlsson, Annelie LU ; Forsander, G ; Ivarsson, Sten LU ; Kockum, I ; Lernmark, Åke LU ; Lindblad, Bengt LU ; Marcus, C and Samuelsson, U
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pediatric Diabetes
- volume
- 13
- pages
- 45 - 50
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000299549900008
- pmid:21910810
- scopus:84856406466
- pmid:21910810
- ISSN
- 1399-543X
- DOI
- 10.1111/j.1399-5448.2011.00807.x
- project
- Better Diabetes Diagnosis (BDD)
- language
- English
- LU publication?
- yes
- id
- 285cccbc-6990-4669-b25f-0664d5bfa6c5 (old id 2168965)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21910810?dopt=Abstract
- date added to LUP
- 2016-04-04 07:42:44
- date last changed
- 2024-01-12 02:21:19
@article{285cccbc-6990-4669-b25f-0664d5bfa6c5, abstract = {{C-peptide in the classification of diabetes in children and adolescents. Aim: To report C-peptide results in newly diagnosed patients and the relation to clinical diagnosis of diabetes. Methods: A nation-wide cohort, the Better Diabetes Diagnosis study was used to determine serum C-peptide at diagnosis in 2734 children and adolescents. Clinical data were collected at diagnosis and follow-up. C-peptide was determined in a validated and controlled time-resolved fluoroimmunoassay. Results: The clinical classification of diabetes, before any information on human leukocyte antigen, islet autoantibodies, or C-peptide was received, was type 1 diabetes (T1D) in 93%, type 2 diabetes (T2D) in 1.9%, maturity onset diabetes of the young (MODY) in 0.8%, secondary diabetes (0.6%), while 3.3% could not be classified. In a random, non-fasting serum sample at diagnosis, 56% of the patients had a C-peptide value >0.2 nmol/L. Children classified as T2D had the highest mean C-peptide (1.83 + 1.23 nmol/L) followed by MODY (1.04 ± 0.71 nmol/L) and T1D (0.28 ± 0.25 nmol/L). Only 1/1037 children who had C-peptide <0.2 nmol/L at diagnosis was classified with a type of diabetes other than T1D. Predictive value of C-peptide >1.0 nmol/L for the classification of either T2D or MODY was 0.46 [confidence interval 0.37-0.58]. Conclusions: More than half of children with newly diagnosed diabetes have clinically important residual beta-cell function. As the clinical diagnosis is not always straightforward, a random C-peptide taken at diagnosis may help to classify diabetes. There is an obvious use for C-peptide determinations to evaluate beta-cell function in children with diabetes.}}, author = {{Ludvigsson, Johnny and Carlsson, Annelie and Forsander, G and Ivarsson, Sten and Kockum, I and Lernmark, Åke and Lindblad, Bengt and Marcus, C and Samuelsson, U}}, issn = {{1399-543X}}, language = {{eng}}, pages = {{45--50}}, publisher = {{Wiley-Blackwell}}, series = {{Pediatric Diabetes}}, title = {{C-peptide in the classification of diabetes in children and adolescents.}}, url = {{http://dx.doi.org/10.1111/j.1399-5448.2011.00807.x}}, doi = {{10.1111/j.1399-5448.2011.00807.x}}, volume = {{13}}, year = {{2012}}, }